Glioblastoma Multiforme Market By Drug Type (Bevacizumab, Carmustine) - Growth, Share, & Competitive Analysis, 2016 - 2022

This report on the global glioblastoma multiforme market studies various drugs used to treat glioblastoma along with pipeline analysis of upcoming potential drugs. Glioblastoma multiforme is the most common and aggressive cancer that begins in the brain. According to the Brain Tumour Foundation of Canada, the incidence of glioblastoma multiforme (GBM) is 2 to 3 per 100,000 people in the United States and Europe. GBM accounts for 12 to 15% of all intracranial tumors and 50 to 60% of astrocytic tumors.

For this study, the various drugs studied include bevacizumab, temozolomide, and carmustine. Market size estimates and forecasts for these segments for 2013 to 2022 are provided in terms of USD Mn, along with the respective CAGRs for 2016 to 2022, considering 2015 as the base year.

The pipeline analysis for the glioblastoma multiforme market comprises projected market sales of Phase III drugs estimated till 2022. The phase III drugs included in the pipeline analysis are TRC-105, VB-111, TOCA 511, DCVax-Brain, Rindopepimut (CDX-110), and others. The report also has information about the drugs in phases II and I of the clinical trials from a qualitative point of view.

The geographic segmentation of the global glioblastoma multiforme market is performed for North America, Europe, Asia-Pacific, and the rest of the world markets. The regions are also further sub-segmented based on major countries. Market size estimates and forecasts for these segments for the period 2013 to 2022 are provided in terms of USD Mn, along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

According to the American Association of Neurological Surgeons (AANS), the National Cancer Institute estimates that 22,850 adults (12,630 men and 10,280 women) were diagnosed with brain and other nervous system cancers in 2015. It also estimates that in 2015, 15,320 of these diagnoses resulted in deaths. Glioblastoma multiforme (GBM) has an incidence of two to three per 100,000 adults per year and accounts for 52% of all primary brain tumors. Overall, GBM accounts for about 17% of all brain tumors (primary and metastatic). It is categorized as one of the orphan diseases with a high mortality rate.

The glioblastoma multiforme market is segmented based on the type of drug:

  • Temozolomide
  • Bevacizumab
  • Carmustine

In 2015, temozolomide accounted for the largest market share of the global glioblastoma multiforme market. The key advantages possessed by temozolomide are delayed progression without impacting the quality of life and fewer adverse effects compared to other molecules. Medical practitioners suggest that combination radiotherapy and temozolomide chemotherapy are currently the standards of care for most patients suffering from GBM. Temozolomide belongs to the class of alkylating agents; the mechanism of action comprises cell destruction initiated by abnormal methylations of DNA bases, and in particular, the formation of O6-alkylguanine in DNA. The DNA repair enzyme-methylguanine-DNA methyltransferase (MGMT) antagonizes the genotoxic effects of alkylating agents. MGMT gene silencing through promoter methylation is a favorable prognostic marker, predicting benefits from this sort of chemotherapy in GBM. Thus, temozolomide is the first-line therapy used for GBM treatment. Still, ongoing research to enhance the efficiency of bevacizumab in GBM treatment might affect the temozolomide market share shortly.

For this study, the global glioblastoma multiforme market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Africa's Middle East

In 2015, North America and Europe dominated the market with around 60% of the overall market share. The key factors assisting the growth of the glioblastoma multiforme market in these regions are mounting support from government and non-government organizations to increase public awareness related to the diagnosis and treatment of GBM and advanced healthcare infrastructure to boost the pipeline of research in this market. Market experts suggest that key GBM treatment drugs are initially approved in these regions as the North American and European markets are the most lucrative pharmaceutical markets. The upcoming pipeline drugs are expected to play a crucial role in the GBM market, where early market entry and high drug prices will be the key factors that will boost the overall GBM market in North America and Europe initially. Asia-Pacific is expected to grow at a significant pace, with Japan being observed as the leading market, followed by China and India. India and China have a large low-and middle-income populations; hence, the demand for low-cost treatments is high. However, in the case of life-threatening diseases such as GBM, the scenario is different as the available treatments are limited and require higher costs.

Frequently Asked Questions:

The market for Glioblastoma Multiforme is expected to reach US$ XX Bn in 2022.

The Glioblastoma Multiforme market is expected to see significant CAGR growth over the coming years, at XX%.

The report is forecasted from 2016-2022.

The base year of this report is 2021.

AbbVie Inc., Activartis GmbH, 6.3 Agenus Inc., Arog Pharmaceuticals, Inc., Celldex Therapeutics, Inc . are some of the major players in the global market

Choose License Type
Trusted By
Published Date:  Jun 2016
Category:  Pharmaceuticals
Report ID:   57903
Report Format:   PDF
Pages:   120
Rating:    4.3 (65)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support